Dose Extension and Costs of Lanreotide Autogel 120 Mg Used in Routine Neuroendocrine Tumors Care In Poland – 2- Years Data From Lanro-Net Study

Abstract Background: A new lanreotide autogel/depot (LAN) syringe was developed based on feedback from a human factors study to improve user experience. Methods: PRESTO was a multinational, simulated-use study in nurses with ≥2 years’ experience injecting LAN or octreotide long-acting release (OCT LAR) in patients with acromegaly and/or neuroendocrine tumors, which aimed to assess injector preference between the LAN new syringe and the current OCT LAR syringe. Participating nurses were invited to test both the LAN new syringe (120 mg) and the current OCT LAR syringe (20 mg or 30 mg), using injection pads. The sponsor was not involved in these sessions. In an anonymous web-based questionnaire, nurses reported overall preference (‘strong’ or ‘slight’; primary endpoint), and rated and ranked the importance of nine attributes for each syringe (1 [not at all] to 5 [very much]). Results: In total, 90 nurses attended injection sessions and completed valid questionnaires. Overall, 97.8% of nurses expressed a preference (85.6% ‘strong’, 12.2% ‘slight’) for LAN new syringe (p<0.0001 vs current OCT LAR). Attribute performance ratings were consistently higher for LAN new syringe vs current OCT LAR, with the greatest differences in ‘fast administration’ and ‘confidence the syringe will not be clogged’ (mean [standard deviation]: 2.6 [1.2] and 2.3 [1.5], respectively; p<0.0001). The attribute ranked most important was ‘confidence the syringe will not be clogged’ (24.4%) and least important was ‘convenience of syringe format, including packaging, from preparation to injection’ (34.4%). Conclusions: The PRESTO study showed that nurses preferred the user experience of the LAN new syringe over the current OCT LAR syringe across all attributes tested.

Download Full-text

Evaluation of the efficacy and the safety of lanreotide autogel 120 mg on tumor growth stabilization in patients with progressive neuroendocrine tumors (NETs) who are not eligible to surgery or chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.e14660 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e14660-e14660 ◽

Cited By ~ 3

Author(s):

M. Martin-Richard ◽

V. Alonso ◽

M. Marmol ◽

D. E. Castellano ◽

E. Fonseca ◽

...

Keyword(s):

Tumor Growth ◽

Neuroendocrine Tumors ◽

Lanreotide Autogel

Download Full-text

Profile of lanreotide autogel and its potential in the treatment of gastroenteropancreatic neuroendocrine tumors

Gastrointestinal Cancer Targets and Therapy ◽

10.2147/gictt.s70701 ◽

2015 ◽

pp. 123

Author(s):

Anja Rinke ◽

Daniela Mueller

Keyword(s):

Neuroendocrine Tumors ◽

Gastroenteropancreatic Neuroendocrine Tumors ◽

Lanreotide Autogel

Download Full-text

Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors

Cancer ◽

10.1002/cncr.22272 ◽

2006 ◽

Vol 107 (10) ◽

pp. 2474-2481 ◽

Cited By ~ 44

Author(s):

Emilio Bajetta ◽

Giuseppe Procopio ◽

Laura Catena ◽

Antonia Martinetti ◽

Sara De Dosso ◽

...

Keyword(s):

Neuroendocrine Tumors ◽

Well Differentiated ◽

Lanreotide Autogel

Download Full-text

Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria

Experimental and Clinical Endocrinology & Diabetes ◽

10.1055/a-1342-2755 ◽

2021 ◽

Vol 129 (07) ◽

pp. 500-509

Author(s):

Anja Rinke ◽

Christoph Maintz ◽

Lothar Müller ◽

Matthias M. Weber ◽

Harald Lahner ◽

...

Keyword(s):

Clinical Practice ◽

Neuroendocrine Tumors ◽

Chromogranin A ◽

Carcinoid Syndrome ◽

Evaluation Criteria ◽

Routine Clinical Practice ◽

Good Tolerability ◽

Multicenter Observational Study ◽

Long Term Treatment ◽

Lanreotide Autogel

Abstract Background The long-acting somatostatin analog lanreotide autogel is effective in the treatment of patients with neuroendocrine tumors. Objective To evaluate the long-term treatment response in patients with neuroendocrine tumors receiving lanreotide autogel in routine clinical practice. Methods Non-interventional, 24-month study in patients with neuroendocrine tumors treated with lanreotide autogel (NCT01840449). Results Patients (n=80) from 26 centers in Germany and Austria were enrolled. Neuroendocrine tumors were mainly grade 1/2, metastasized, intestinal, and associated with carcinoid syndrome; 88.9% had received previous neuroendocrine tumor treatment. Of those, 84.4% had previous surgery, 18.7% had received octreotide. The primary endpoint, defined by a <50% chromogranin A increase at month 12 compared with the lowest value between baseline and month 3 was achieved by 89.5% patients. Stable disease according to Response Evaluation Criteria in Solid Tumors 1.1 was observed in 76.9 and 75.0% patients at months 12 and 24 of lanreotide treatment, respectively. Mean change of chromogranin A levels from baseline to month 24 was −0.12 × upper limit of normal (95% CI, −0.22; −0.45). In a post hoc analysis, 38.5% of the subgroup of patients with carcinoid syndrome had daily diarrhea at baseline vs. 21.4% at month 24. At baseline, 27.8% of patients received lanreotide 120 mg every 4 weeks vs. 56.7% at month 24. Quality of life data were heterogeneous. No new safety issues arose and/or required further investigation. Conclusions Our study reflects routine lanreotide autogel use in patients with advanced/metastatic neuroendocrine tumors. This analysis shows effectiveness with stabilization of disease-related symptoms and good tolerability of lanreotide autogel in clinical practice.

Download Full-text